Open AccessSevere Cholestatic Hepatitis due to Temozolomide
Author(s) -
Antonio Grieco,
Maria Antonietta Tafuri,
Barbara Diletto,
Nicola Napoli,
Nicola Balducci,
Fabio Maria Vecchio,
Luca Miele
Publication year - 2015
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000000476
Subject(s) - temozolomide , medicine , adverse effect , adjuvant , radiation therapy , toxicity , liver function , oncology , liver function tests , gastroenterology
Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period. Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m 2 . The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.